HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for claims directed to the use of HCW9302 to treat Alopecia Areata. HCW Biologics develops fusion immunotherapeutics to treat diseases...
HCW Biologics (HCWB) reported findings supporting its TGF-ß trap and IL-15 fusion as a potential immunotherapeutic enhancer. Human studies showed expansion of progenitor CD8+ T cells and NK cells, while preclinical data demonstrated anti-tumor activity. The company has incorporated the fusion into two second-generation candidates, with clinical studies planned for 2027.
HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, reported financial results for the second quarter reflecting a wider net loss. In addition, the company provided an update citing funding needs. HCW Biologics develops fusion immunotherapies to treat chronic inflammation, including...
HCW Biologics Inc. (HCWB) announced a 1-for-6 reverse stock split that will take effect before markets open on June 30, 2026. The move is designed to help the company maintain its listing after receiving specific requirements from a Nasdaq Hearings Panel.
HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, Friday announced that it has been approved for a 1-for-6 reverse stock split of the company's common stock, with par value of $0.0001, effective June 30. The company decided to commence a reverse stock split after it received a...
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.